Friday, September 30, 2022

561.316.3330

Biotechnology News Magazine

Quanterix Receives Funding from the Alzheimer’s Drug Discovery Foundation to Accelerate Alzheimer’s Disease Diagnostic Plasma Test Development

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced it has partnered with the Alzheimer’s Drug Discovery Foundation (ADDF) to accelerate development of a multi-analyte plasma test for early detection of Alzheimer’s disease. As part of the partnership, the ADDF will fund a series of prospective clinical trials to validate the test in collaboration with Amsterdam University Medical Centers (Amsterdam UMC).

Charlotte Teunissen, professor and principal clinical investigator, will lead the clinical trials at Amsterdam UMC. The financial terms for this agreement have not been disclosed. The work will be coordinated through the Company’s Simoa® Accelerator Services Lab, a flagship laboratory providing contract research services and clinical sample testing, powering the research of more than 400 companies and accelerating drug approval timelines through the detection of biomarkers at the lowest possible levels.

“The ADDF is a well-established philanthropic organization with a strong leadership position in the field and we look forward to partnering with them in our quest to validate a Simoa plasma test for Alzheimer’s disease,” said Kevin Hrusovsky, Chairman and Chief Executive Officer, Quanterix and Founder of Powering Precision Health (PPH). “We are pleased to receive ADDF funding aimed at accelerating development of a multi-analyte test, as Alzheimer’s disease continues to be one of the largest threats to global public health, with an enormous economic toll. It’s now more important than ever to develop highly accessible diagnostic tests to aid in linking Alzheimer’s patients with emerging therapies at the earliest onset of disease.”

“We are in a historic moment with plasma-based biomarkers for Alzheimer’s disease detection nearing clinical implementation. This partnership and funding with the ADDF will help further drive the rapid progress in this area just in time for the arrival of new therapeutics. We will be looking to validate the Simoa multi-analyte test for use in both memory care and primary care settings, in persons with worries about their cognition,” said Charlotte Teunissen, Professor and Principal Investigator at Amsterdam UMC.

The mission of the ADDF is to rapidly accelerate the discovery of drugs to prevent, treat and cure Alzheimer’s disease. Founded in 1998 by Leonard A. and Ronald S. Lauder, the ADDF is the only public charity solely focused on funding the development of drugs for Alzheimer’s disease. Through the support of its donors, the ADDF has awarded more than $209 million to fund over 690 Alzheimer’s drug discovery programs, biomarker programs and clinical trials in 19 countries.

“We have long believed the path to approved Alzheimer’s treatments starts with a better way to diagnose patients and monitor their response to therapy. Through the Diagnostics Accelerator, the ADDF is accelerating the development of novel biomarkers for the early detection of Alzheimer’s disease and related dementias, which are essential to driving research forward, allowing us to enroll the right patients in clinical trials and track their progress,” said Howard Fillit, Co-Founder and Chief Science Officer of the ADDF. “Cutting-edge diagnostic tools like the multi-analyte blood test being developed by Quanterix also have the potential to greatly improve accuracy and facilitate early diagnosis in clinical practice.”

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine